dc.creator | Vallejo Vaz, Antonio Javier | es |
dc.creator | Lawrence A. Leiter | es |
dc.creator | Stefano del Prato | es |
dc.creator | Marja-Riitta Taskinen | es |
dc.creator | Dirk Müller-Wieland | es |
dc.creator | Maja Bujas-Bobanovic | es |
dc.creator | Alexia Letierce | es |
dc.creator | Jonas Mandel | es |
dc.creator | Rita Samuel | es |
dc.creator | Kausik K. Ray | es |
dc.date.accessioned | 2023-07-18T11:24:11Z | |
dc.date.available | 2023-07-18T11:24:11Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Vallejo Vaz, A.J., Lawrence A. Leiter, , Stefano del Prato, , Marja-Riitta Taskinen, , Dirk Müller-Wieland, , Maja Bujas-Bobanovic, ,...,Kausik K. Ray, (2020). Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 27 (15), 1663-1674. https://doi.org/10.1177/2047487320905185. | |
dc.identifier.issn | 2047-4873 | es |
dc.identifier.issn | 2047-4881 | es |
dc.identifier.uri | https://hdl.handle.net/11441/148044 | |
dc.description.abstract | Aims: Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on non-high-density lipoprotein cholesterol goal attainment in 10 phase 3 trials with alirocumab versus control (n = 4983).
Methods: Trials were grouped into four pools based on alirocumab dose (75-150 mg every 2 weeks), control (placebo/ezetimibe) and statin use. Baseline triglyceride quintiles were built within each pool. Non-high-density lipoprotein cholesterol goal attainment (very high risk: <100 mg/dl; moderate/high risk: <130 mg/dl), low-density lipoprotein cholesterol goal attainment (very high risk: <70 mg/dl; moderate/high risk: <100 mg/dl) and changes from baseline in lipid parameters were assessed at Week 24 among baseline triglyceride quintiles.
Results: Higher baseline triglycerides were associated with a worse cardiovascular risk profile. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol increased with higher triglycerides, but the magnitude in non-high-density lipoprotein cholesterol was three- to four-fold higher compared with the increase in low-density lipoprotein cholesterol. Non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol percentage reductions from baseline with alirocumab were similar regardless of baseline triglycerides. A greater proportion of alirocumab-treated patients attained non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol goals compared with placebo or ezetimibe. Unlike low-density lipoprotein cholesterol goal attainment, non-high-density lipoprotein cholesterol goal attainment significantly declined with increasing baseline triglycerides (p < 0.05 for trend tests). A single standard deviation increase in baseline log(triglycerides) was significantly associated with lower odds ratios of attaining non-high-density lipoprotein cholesterol goals in the different pools and treatment (alirocumab/placebo/ezetimibe) groups, unlike low-density lipoprotein cholesterol goal attainment.
Conclusion: Individuals with increased triglycerides have higher non-high-density lipoprotein cholesterol levels and lower rates of non-high-density lipoprotein cholesterol goal attainment (unlike low-density lipoprotein cholesterol goal attainment). Alirocumab improves non-high-density lipoprotein cholesterol goal attainment in this population. These results highlight the impact of triglycerides on non-high-density lipoprotein cholesterol and the need for novel therapies targeting triglyceride-related pathways. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 pág. | es |
dc.language.iso | eng | es |
dc.publisher | Oxford University Press | es |
dc.relation.ispartof | European Journal of Preventive Cardiology, 27 (15), 1663-1674. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Alirocumab | es |
dc.subject | Goal attainment | es |
dc.subject | Low-density lipoprotein cholesterol | es |
dc.subject | Non-high-density lipoprotein cholesterol | es |
dc.subject | Proprotein convertase subtilisin/kexin type 9 | es |
dc.subject | Triglycerides | es |
dc.title | Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://academic.oup.com/eurjpc/article/27/15/1663/5950574 | es |
dc.identifier.doi | 10.1177/2047487320905185 | es |
dc.journaltitle | European Journal of Preventive Cardiology | es |
dc.publication.volumen | 27 | es |
dc.publication.issue | 15 | es |
dc.publication.initialPage | 1663 | es |
dc.publication.endPage | 1674 | es |
dc.contributor.funder | Regeneron Pharmaceuticals, Inc. | es |
dc.contributor.funder | Sanofi | es |